Opioid-free Anaesthesia in Breast Cancer Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-99
SponsorUniversity of Ioannina

About this trial

Background:

Various analgesic modalities are adopted for perioperative analgesia in breast cancer surgeries. Opioid-free and opioid-sparing techniques are gaining popularity due to the lack of opioid-dependent undesirable effects, including respiratory depression, urinary retention, nausea and vomiting, constipation, itching, opioid-induced hyperalgesia, tolerance, addiction, and immune system disorders.

The goal of this prospective randomized clinical trial is to investigate the impact of opioid-free anaesthesia (OFA) versus conventional general anaesthesia (CGA) on postoperative analgesic requirements after breast cancer surgery (lumpectomy/mastectomy, with or without axillary lymph node excision).

Secondary objectives include comparative perioperative evaluation of cognitive function and postoperative adverse events during the first 48 hours atfter surgery. Comparative evaluation of intraoperative haemodynamics and hospital length of stay are also secondary objectives, as well as the incidence of neuropathic pain assessed by validated questionnaires at 3 and 6 months postoperatively.

During the preoperative screening, body measurements, age, gender, ASA (American Society of Anesthesiologists) physical status classification, educational level (using a 6-level scale: elementary, middle school, high school, higher education, higher education, and postgraduate/doctoral degree), home medication, and comorbidities (using the Charlson Comorbidity Index) are recorded.

Intraoperatively, the duration of anaesthesia, duration of surgery, associated intraoperative data (e.g., haemodynamic instability, adverse effects associated with protocol-administered pharmaceutical agents, etc.), and medications administered (type and quantity) are recorded.

The investigators expect to recruit at least 100 participants per group.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

adult patients

breast cancer surgery (mastectomy, lumpectomy, with or without lymph node excision) under general anaesthesia

Disqualifiers

under 18 years

patient refusal

opioid use (systemic or not) for any reason (e.g., chronic malignant pain)

language barrier (difficulty in communicating in Greek language)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Opioid Free Anaesthesia (OFA)

    Other intervention

    Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.

  • Conventional General Anaesthesia (CGA)

    Other intervention

    Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Opioid Free Anaesthesia (OFA group)Experimental treatment 1 intervention
Group B: Conventional general anaesthesia (CGA group)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Postoperative analgesia.

Postoperative level of analgesia assessed by the NRS (Numerical Rating Scale, ranging from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable).

Time frame
From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.
2

Postoperative consumption of opioids.

Total postoperative consumption of opioids.

Time frame
From PACU (Post Anaesthesia Care Unit) admission to 48 hours postoperatively.

Secondary outcomes

1

Perioperative blood pressure measurements.

Intermittent blood pressure measurements (every 5 minutes) - blood pressure measured in mmHg.

Time frame
From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.
2

Perioparative pulse measurements.

Intermittent arterial pulse measurements (every 5 minutes) - measured in beats per minute.

Time frame
From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.
3

Perioperative consumption of ephedrine.

Total intravenous consumption of ephedrine, measured in milligrams.

Time frame
From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.
4

Perioperative consumption of atropine.

Total intravenous consumption of atropine, measured in milligrams.

Time frame
From the beginning of surgery to PACU (Post Anaesthesia Care Unit) discharge, assessed up to 48 hours.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.